By Stephen Nakrosis

Merck & Co. Inc. on Tuesday said Health Canada gave conditional approval for Keytruda in combination with chemotherapy to treat certain patients with breast cancer.

The conditional approval was given to treat certain patients with metastatic triple-negative breast cancer who haven't received prior chemotherapy for metastatic disease, the company said.

Health Canada's decision is based on results from the Phase 3 KEYNOTE-355 trial, Merck said. The trial "showed that Keytruda in combination with chemotherapy demonstrated a statistically significant improvement in progression free survival compared to patients treated with placebo in combination with chemotherapy," Merck said.

According to Merck, breast cancer is the second leading cause of death from cancer in Canadian women.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

November 23, 2021 11:40 ET (16:40 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Merck Charts.